Arbutus Biopharma Corporation (ABUS): Price and Financial Metrics


Arbutus Biopharma Corporation (ABUS): $2.52

0.04 (+1.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABUS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ABUS POWR Grades

  • ABUS scores best on the Sentiment dimension, with a Sentiment rank ahead of 88.65% of US stocks.
  • ABUS's strongest trending metric is Momentum; it's been moving up over the last 178 days.
  • ABUS ranks lowest in Stability; there it ranks in the 22nd percentile.

ABUS Stock Summary

  • Of note is the ratio of ARBUTUS BIOPHARMA CORP's sales and general administrative expense to its total operating expenses; merely 7.26% of US stocks have a lower such ratio.
  • For ABUS, its debt to operating expenses ratio is greater than that reported by only 7.42% of US equities we're observing.
  • As for revenue growth, note that ABUS's revenue has grown 253.85% over the past 12 months; that beats the revenue growth of 96.4% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to ARBUTUS BIOPHARMA CORP, a group of peers worth examining would be CNCE, KZIA, HGEN, AUTL, and PSTX.
  • ABUS's SEC filings can be seen here. And to visit ARBUTUS BIOPHARMA CORP's official web site, go to www.arbutusbio.com.

ABUS Valuation Summary

  • ABUS's EV/EBIT ratio is -5.9; this is 167.82% lower than that of the median Healthcare stock.
  • ABUS's EV/EBIT ratio has moved down 3.3 over the prior 157 months.

Below are key valuation metrics over time for ABUS.

Stock Date P/S P/B P/E EV/EBIT
ABUS 2022-12-02 10.8 2.7 -5.6 -5.9
ABUS 2022-12-01 10.1 2.5 -5.3 -5.5
ABUS 2022-11-30 10.2 2.5 -5.3 -5.5
ABUS 2022-11-29 10.4 2.6 -5.4 -5.6
ABUS 2022-11-28 11.2 2.8 -5.8 -6.1
ABUS 2022-11-25 11.6 2.9 -6.0 -6.3

ABUS Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at 58.45%.
  • Its 3 year revenue growth rate is now at 313.57%.
  • Its 5 year cash and equivalents growth rate is now at 12.83%.
Over the past 15 months, ABUS's revenue has gone up $27,629,000.

The table below shows ABUS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 35.98 -37.972 -69.419
2022-06-30 33.368 -35.316 -76.097
2022-03-31 21.456 -29.032 -84.558
2021-12-31 10.988 -67.532 -88.386
2021-09-30 10.168 -62.939 -86.656
2021-06-30 8.351 -59.077 -84.193

ABUS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ABUS has a Quality Grade of D, ranking ahead of 23.96% of graded US stocks.
  • ABUS's asset turnover comes in at 0.061 -- ranking 309th of 681 Pharmaceutical Products stocks.
  • ABBV, PLXP, and HSTO are the stocks whose asset turnover ratios are most correlated with ABUS.

The table below shows ABUS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.061 1 -1.012
2021-03-31 0.059 1 -1.139
2020-12-31 0.059 1 -1.030
2020-09-30 0.056 1 -1.204
2020-06-30 0.073 1 -2.668
2020-03-31 0.053 1 -3.000

ABUS Price Target

For more insight on analysts targets of ABUS, see our ABUS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.90 Average Broker Recommendation 1.7 (Moderate Buy)

ABUS Stock Price Chart Interactive Chart >

Price chart for ABUS

ABUS Price/Volume Stats

Current price $2.52 52-week high $4.67
Prev. close $2.48 52-week low $1.85
Day low $2.45 Volume 90,675
Day high $2.55 Avg. volume 1,405,012
50-day MA $2.31 Dividend yield N/A
200-day MA $2.51 Market Cap 377.88M

Arbutus Biopharma Corporation (ABUS) Company Bio


Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. The company is based in Burnaby, Canada.


ABUS Latest News Stream


Event/Time News Detail
Loading, please wait...

ABUS Latest Social Stream


Loading social stream, please wait...

View Full ABUS Social Stream

Latest ABUS News From Around the Web

Below are the latest news stories about ARBUTUS BIOPHARMA CORP that investors may wish to consider to help them evaluate ABUS as an investment opportunity.

Arbutus Biopharma Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag

Arbutus Biopharma ( NASDAQ:ABUS ) Third Quarter 2022 Results Key Financial Results Revenue: US$5.95m (up 78% from 3Q...

Yahoo | November 11, 2022

Analysts Offer Insights on Healthcare Companies: Arbutus Biopharma (ABUS), Kala Pharmaceuticals (KALA) and TScan Therapeutics (TCRX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arbutus Biopharma (ABUS – Research Report), Kala Pharmaceuticals (KALA – Research Report) and TScan Therapeutics (TCRX – Research Report) with bullish sentiments. Arbutus Biopharma (ABUS) H.C. Wainwright analyst Ed Arce maintained a Buy rating on Arbutus Biopharma today and set a price target of $6.00. The company's shares closed last Wednesday at $2.44, close to its 52-week low of $1.85. According to TipRanks.com, Arce is a 4-star analyst with an average return of -26.0% and a 25.8% success rate.

Howard Kim on TipRanks | November 10, 2022

JMP Securities Sticks to Their Buy Rating for Arbutus Biopharma (ABUS)

JMP Securities analyst Roy Buchanan reiterated a Buy rating on Arbutus Biopharma (ABUS - Research Report) today and set a price target of $6.00. The company's shares opened today at $2.34.Buchanan covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma, Dynavax, and PolyPid. According to TipRanks, Buchanan has an average return of -31.1% and a 19.35% success rate on recommended stocks. Arbutus Biopharma has an analyst consensus of Strong Buy, with a price target consensus of $6.50, which is a 177.78% upside from current levels. In a report released on November 4, Chardan Capital also reiterated a Buy rating on the stock with a $6.00 price target.

Howard Kim on TipRanks | November 9, 2022

Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates

Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | November 9, 2022

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before year end Conference call and webcast today at 8:45 AM ET WARMINSTER, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveragin

Yahoo | November 9, 2022

Read More 'ABUS' Stories Here

ABUS Price Returns

1-mo -1.18%
3-mo 19.43%
6-mo -5.97%
1-year -39.28%
3-year 10.04%
5-year -50.59%
YTD -35.22%
2021 9.58%
2020 27.70%
2019 -27.42%
2018 -24.16%
2017 106.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7036 seconds.